SCHEMBL24672696

SCHEMBL24672696

CC(=O)N1CCC(OCCCC(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.41
RORC P51449 1/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LSS P48449 1/20 0.36
LNPEP Q9UIQ6 1/20 0.36
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.35
NAMPT P43490 1/20 0.34
LMNA P02545 1/20 0.34
EPHX2 P34913 2/20 0.34
EPHX1 P07099 1/20 0.34
GBA1 P04062 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23560455 0.86 CHRNB2 (0.37) MEN1KMT2ALSSHSD17B10ALDH1A1
SCHEMBL23568087 0.86 ITGB3 (0.36) LSSHSD17B10NAMPTGBA1
SCHEMBL25728303 0.85 EPHX2 (0.39) PIK3CDLSSHSD17B10ALDH1A1EPHX2
SCHEMBL25479442 0.84 LSS (0.34) LSSHSD17B10NAMPTGBA1
SCHEMBL22856426 0.82 ALDH1A1 (0.46) RAB9ALSSKDM4EUSP2ALDH1A1
SCHEMBL6134357 0.81 HPGD (0.45) RAB9AUSP2ALDH1A1EPHX1
SCHEMBL9030287 0.81 KMT2A (0.39) RAB9AMEN1KMT2ALSSNAMPT
SCHEMBL23945997 0.80 PIK3CD (0.46) PIK3CDRORCRAB9ALNPEPEPHX2
SCHEMBL21106934 0.80 CHRNB2 (0.34) MEN1KMT2ALSSHSD17B10ALDH1A1
SCHEMBL24379948 0.80 HSD17B10 (0.32) KMT2ALSSHSD17B10NAMPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 PIK3CD 421/4885RORC 414/4885RAB9A 3619/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PIK3CD 321/4885RORC 650/4885RAB9A 4270/4885
US-11707457-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PIK3CD 321/4885RORC 650/4885RAB9A 4270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.